Grit Biotherapeutics Presents GT801 at the ASH Annual Meeting
Grit Biotherapeutics Co., Ltd. (NASDAQ: GRTB) is thrilled to announce that its revolutionary GT801 in vivo CAR-T therapy has been selected for an oral presentation at the prestigious American Society of Hematology (ASH) Annual Meeting. This event is slated for December in Orlando and promises to showcase incredible advancements in the field of immunotherapy.
Highlighting Innovative Advances in CAR-T Therapy
Under the guidance of Professor Pin Wang, the presentation will focus on the abstract titled "Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNA Delivery: Toward Scalable and Translatable Cell Therapy." This session agrees with Grit Bio's commitment to leading the charge in CAR-T cell therapies, which have been transformative in treating various blood cancers.
Understanding GT801 and Its Mechanism
GT801 is a groundbreaking anti-CD19 therapy that stands out due to its use of T-cell-targeted lipid nanoparticles (T-LNPs), which carry optimized mRNA. By leveraging proprietary CLAMP technology, which facilitates site-specific antibody conjugation, Grit Biotherapeutics achieves unparalleled precision in T-cell targeting while ensuring minimal unintended effects on other cell types. This method significantly enhances the durability and safety of CAR expression.
Preclinical Insights and Implications
In preclinical investigations, GT801 has demonstrated remarkable effectiveness. For instance, studies have shown more than 95% B-cell clearance utilizing doses as low as 0.01 mg/kg and an impressive >80% CAR expression in tissue-resident T cells. Importantly, the off-target delivery to other cell types remains less than 1%, which underscores the targeted nature of this therapeutic approach.
Robust CAR Expansion and Safety Profile
An additional notable finding includes the 30-fold expansion of CAR-T cells within the body, accompanied by minimal cytokine release, which proves the safety of repeated dosing. These preclinical results set a solid foundation for the promising therapeutic efficacy of GT801.
Reinforcing Commitment to Patient-Centric Innovations
Initial clinical data support the preclinical findings by demonstrating efficient CAR expression and deep B-cell depletion while confirming the tolerability of repeat dosing. The strengthening of GT801 as an off-the-shelf immunotherapy candidate signals a new era of accessible treatments that can significantly impact patient health.
Acknowledgment of Leadership in the Field
Dr. Yarong Liu, Chairman and CEO of Grit Biotherapeutics, highlighted the significance of this invitation to present at ASH 2025. He noted that this opportunity reflects the international acknowledgment of Grit Bio’s pioneering role in in vivo CAR-T innovations. The excitement surrounding GT801 reflects a shifting paradigm in the cell therapy landscape—moving away from complex manufacturing processes towards achievable and efficient solutions.
About Grit Biotherapeutics
Founded in 2019, Grit Biotherapeutics stands at the forefront of innovation in biopharmaceuticals, focusing on developing next-generation immunotherapies suited for cancer and autoimmune diseases. The organization’s research and development efforts primarily target TIL-based therapies alongside other cell therapies intended for solid tumors and hematologic malignancies. Among Grit's standout products is GT101, the first TIL therapy approved for trials in China, while GT201 is recognized as the world’s first membrane-bound IL-15 complex-engineered TIL product.
Frequently Asked Questions
What is GT801?
GT801 is an innovative in vivo CAR-T therapy focused on treating cancer, specifically targeting CD19.
Who will present the GT801 findings at ASH?
Professor Pin Wang, the Chief Scientific Officer of Grit Biotherapeutics, will deliver the presentation.
What challenges does GT801 aim to address?
GT801 strives to simplify the complex manufacturing processes of CAR-T therapies, making them more scalable and effective.
How has GT801 performed in preclinical studies?
Preclinical results show high effectiveness, including over 95% B-cell clearance and substantial CAR expansion with a favorable safety profile.
What is Grit Biotherapeutics’ mission?
Grit Biotherapeutics aims to innovate and provide next-generation immunotherapies for cancer and autoimmune patients worldwide.
